Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Abbott Adds To Renal Pipeline In Deal With Action Pharma

May 03 2012

• By Paul Bonanos

Related Content

Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug

Sep 23 2010

Sanofi Delay Boosts Novo's Bid For Insulin Dominance

Aug 04 2011

Abbott Pays Top Dollar For Galapagos’ Autoimmune Drug

Feb 29 2012

Abbott Spin-Off AbbVie To Remain Close To Its Roots

Mar 21 2012

Reata Readies Bardoxolone For Phase III Looking At Kidney Function Outcomes

Jun 24 2011

Abbott Pays $400 Million Upfront For Reata’s Preclinical AIM Programs

Dec 12 2011

Related Companies

Abbott

Action Pharma A/S

Zealand Pharma A/S

Reata Pharmaceuticals, Inc.

Sanofi

Galapagos NV

Additional Topics

United States Denmark Europe Deals BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window